goodrx wegovy - Search News

News

Novo Nordisk, GoodRX, CVS

Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk’s breakup with Hims

The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications. Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service,

The Hill · 19m

Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week,

The Pharma Letter · 11h

GoodRx and Novo Nordisk unveil $499 monthly offer for Ozempic and Wegovy

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy (semaglutide) available to eligible self-paying patients for $499 per month.

Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...

What's Going On With Hims & Hers Shares Today?

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

12h

How GoodRx CEO Wendy Barnes is trying to halve the cost of GLP-1 obesity drugs

In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...

Novo Nordisk slashes price of Ozempic to $499 for cash-paying, uninsured patients

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

1don MSN

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk stock rises, Wegovy approved to treat liver disease

Shares of Novo Nordisk (NVO) are rising early Monday after the US Food and Drug Administration approved Wegovy to treat ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results